Eradication of staphylococcus aureus biofilm infections using synthetic antimicrobial peptides
Zapotoczna, Marta Forde, Éanna Hogan, Siobhan Humphreys, Hilary O’Gara, James P Fitzgerald-Hughes, Deirdre Devocelle, Marc O’Neill, Eoghan
Zapotoczna, Marta
Forde, Éanna
Hogan, Siobhan
Humphreys, Hilary
O’Gara, James P
Fitzgerald-Hughes, Deirdre
Devocelle, Marc
O’Neill, Eoghan
Publication Date
2017-02-07
Type
Article
Downloads
Citation
Zapotoczna, Marta; Forde, Éanna; Hogan, Siobhan; Humphreys, Hilary; O’Gara, James P; Fitzgerald-Hughes, Deirdre; Devocelle, Marc; O’Neill, Eoghan (2017). Eradication of staphylococcus aureus biofilm infections using synthetic antimicrobial peptides. The Journal of Infectious Diseases 215 (6), 975-983
Abstract
Here, we demonstrate that antimicrobial peptides (AMPs) are an effective antibiofilm treatment when applied as catheter lock solutions (CLSs) against S. aureus biofilm infections. The activity of synthetic AMPs (Bac8c, HB43, P18, Omiganan, WMR, Ranalexin, and Polyphemusin) was measured against early and mature biofilms produced by methicillin-resistant S. aureus and methicillin-susceptible S. aureus isolates from patients with device-related infections grown under in vivo-relevant biofilm conditions. The cytotoxic and hemolytic activities of the AMPs against human cells and their immunomodulatory potential in human blood were also characterized. The D-Bac8c2,5Leu variant emerged as the most effective AMP during in vitro studies and was also highly effective in eradicating S. aureus biofilm infection when used in a CLS rat central venous catheter infection model. These data support the potential use of D-Bac8c2,5Leu, alone or in combination with other AMPs, in the treatment of S. aureus intravenous catheter infections.
Funder
Publisher
Oxford University Press (OUP)
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland